PHARVARIS NV (PHVS) Stock News
NASDAQ:PHVS - Nasdaq - NL00150005Y4 - Common Stock - Currency: USD
PHVS Latest News and Analysis
Pharvaris Outlines 2025 Strategic Priorities
Pharvaris Outlines 2025 Strategic Priorities
Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data...
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at...
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and oral convenience
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
Pharvaris to Host Virtual Investor Event on October 23, 2024
Pharvaris to Host Virtual Investor Event on October 23, 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is...
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a...
Pharvaris Presents Data at the Bradykinin Symposium 2024
Pharvaris Presents Data at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin...
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024.
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharvaris (NASDAQ:PHVS) just reported results for the second quarter of 2024.Ph...
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of...
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by...
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024.
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharvaris (NASDAQ:PHVS) just reported results for the first quarter of 2024.Pha...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled...